Zhangzhou Pientzehuang Pharmaceutical., Ltd
600436
株式のランク
#1902
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a Chinese company,... Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a Chinese company, headquartered in Zhangzhou, that specializes in the production and distribution of traditional Chinese medicines. Its offerings, predominantly sold under the renowned Pien Tze Huang brand, reach consumers both domestically within China and across international markets. Beyond its core pharmaceutical products, the company's expansive portfolio encompasses health and wellness items, beauty care products, household chemical goods, a variety of medical devices, and nutritional supplements. The firm operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
株価
$18.20
時価総額
$10.98B
変化（1日）
-0.71%
変化（1年）
-28.52%
国
CN
取引 Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436)
カテゴリー
Healthcare
Zhangzhou Pientzehuang Pharmaceutical., Ltd（600436）の収益
Oct 2026 時点の収益 TTM: 0
Zhangzhou Pientzehuang Pharmaceutical., Ltd の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Zhangzhou Pientzehuang Pharmaceutical., Ltd の収益履歴（2001 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2025 | $1.29B | -12.95% |
| 2024 | $1.48B | 4.01% |
| 2023 | $1.42B | 12.74% |
| 2022 | $1.26B | -0.13% |
| 2021 | $1.26B | 26.63% |
| 2020 | $996.65M | 21.28% |
| 2019 | $821.78M | 18.60% |
| 2018 | $692.90M | 21.38% |
| 2017 | $570.83M | 71.65% |
| 2016 | $332.56M | 14.53% |
| 2015 | $290.38M | 23.71% |
| 2014 | $234.72M | 2.00% |
| 2013 | $230.12M | 22.53% |
| 2012 | $187.81M | 15.90% |
| 2011 | $162.05M | 23.32% |
| 2010 | $131.40M | 29.13% |
| 2009 | $101.76M | 6.87% |
| 2008 | $95.22M | 17.23% |
| 2007 | $81.22M | 21.42% |
| 2006 | $66.90M | 28.93% |
| 2005 | $51.89M | 69.39% |
| 2004 | $30.63M | 18.68% |
| 2003 | $25.81M | 0.75% |
| 2002 | $25.62M | 9.33% |
| 2001 | $23.43M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $79.67B | - |
US
|
|
| $99.34B | - |
US
|
|
| $64.39B | - |
US
|
|
| $66.40B | - |
US
|
|
| $77.52B | - |
CH
|
